CA3058375C - NIRAPARIB COMPOSITIONS - Google Patents

NIRAPARIB COMPOSITIONS

Info

Publication number
CA3058375C
CA3058375C CA3058375A CA3058375A CA3058375C CA 3058375 C CA3058375 C CA 3058375C CA 3058375 A CA3058375 A CA 3058375A CA 3058375 A CA3058375 A CA 3058375A CA 3058375 C CA3058375 C CA 3058375C
Authority
CA
Canada
Prior art keywords
composition
piperidin
phenyl
indazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3058375A
Other languages
English (en)
French (fr)
Other versions
CA3058375A1 (en
Inventor
George Wu
John Chaber
Arlene E. McKeown
Jennifer R. Foley
Original Assignee
Merck Sharp and Dohme LLC
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63676949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3058375(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC, Tesaro Inc filed Critical Merck Sharp and Dohme LLC
Publication of CA3058375A1 publication Critical patent/CA3058375A1/en
Application granted granted Critical
Publication of CA3058375C publication Critical patent/CA3058375C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
CA3058375A 2017-03-27 2018-03-27 NIRAPARIB COMPOSITIONS Active CA3058375C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477411P 2017-03-27 2017-03-27
US62/477,411 2017-03-27
PCT/US2018/024603 WO2018183354A1 (en) 2017-03-27 2018-03-27 Niraparib compositions

Publications (2)

Publication Number Publication Date
CA3058375A1 CA3058375A1 (en) 2018-10-04
CA3058375C true CA3058375C (en) 2025-05-06

Family

ID=63676949

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3058375A Active CA3058375C (en) 2017-03-27 2018-03-27 NIRAPARIB COMPOSITIONS

Country Status (14)

Country Link
US (3) US11091459B2 (https=)
EP (1) EP3600314A1 (https=)
JP (1) JP2020512350A (https=)
KR (1) KR20200014736A (https=)
CN (1) CN110944638A (https=)
AU (2) AU2018246214B2 (https=)
BR (1) BR112019020211A2 (https=)
CA (1) CA3058375C (https=)
EA (1) EA201992177A1 (https=)
IL (1) IL269630A (https=)
MX (1) MX2019011496A (https=)
SG (1) SG11201909011PA (https=)
TW (1) TWI761476B (https=)
WO (1) WO2018183354A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
CN111918667A (zh) 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
JP2022504228A (ja) 2018-10-03 2022-01-13 テサロ， インコーポレイテッド ニラパリブ遊離塩基の結晶形態
WO2020072860A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
TWI905184B (zh) * 2020-05-08 2025-11-21 比利時商健生藥品公司 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌
JP2024525881A (ja) 2021-07-19 2024-07-12 ヤンセン ファーマシューティカ エヌ．ベー． ニラパリブ（ｎｉｒａｐａｒｉｂ）による転移性去勢抵抗性前立腺癌の治療
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CA3257870A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES
CN121311226A (zh) 2023-05-17 2026-01-09 特沙诺有限公司 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2647545C (en) 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
KR101653548B1 (ko) * 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
MY156873A (en) * 2009-08-26 2016-04-15 Cephalon Inc Novel forms of a multicyclic compound
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
US9191894B2 (en) * 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
CA2935857C (en) 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
HUE062258T2 (hu) 2015-07-02 2023-10-28 Acerta Pharma Bv (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamid szilárd alakjai és készítményei
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
KR20190130625A (ko) 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
US20210106574A1 (en) 2017-12-27 2021-04-15 Tesaro, Inc. Methods of Treating Cancer
CN111918667A (zh) 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
JP2022504228A (ja) * 2018-10-03 2022-01-13 テサロ， インコーポレイテッド ニラパリブ遊離塩基の結晶形態
CA3087392A1 (en) * 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate

Also Published As

Publication number Publication date
IL269630A (en) 2019-11-28
US20230416223A1 (en) 2023-12-28
US20200017462A1 (en) 2020-01-16
EA201992177A1 (ru) 2020-02-25
BR112019020211A2 (pt) 2020-04-22
EP3600314A1 (en) 2020-02-05
AU2018246214B2 (en) 2021-07-08
TWI761476B (zh) 2022-04-21
KR20200014736A (ko) 2020-02-11
CN110944638A (zh) 2020-03-31
AU2018246214A1 (en) 2019-11-07
MX2019011496A (es) 2020-01-23
US11673877B2 (en) 2023-06-13
CA3058375A1 (en) 2018-10-04
WO2018183354A1 (en) 2018-10-04
TW201840315A (zh) 2018-11-16
US20210403448A1 (en) 2021-12-30
JP2020512350A (ja) 2020-04-23
SG11201909011PA (en) 2019-10-30
AU2021245223A1 (en) 2021-11-04
US11091459B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
US11673877B2 (en) Niraparib compositions
US20240082231A1 (en) Niraparib formulations
EP3641742B1 (en) Hydroxynorketamine for the use in the treatment of depression
KR102116087B1 (ko) 리카르바제핀 아세테이트를 포함하는 경구 투여형
EP2200599B1 (en) 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
KR20260048646A (ko) 엔독시펜을 제조 및 사용하는 방법
WO2015102826A1 (en) Novel compositions
US20060034911A1 (en) New oral immediated release dosage form
JP2019529502A (ja) アルツハイマー病及びパーキンソン病を処置するための組成物及び方法
EP2976067B1 (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
KR101506627B1 (ko) 아세브로필린 및 친수성 서방기제를 포함하는 서방형 약학 조성물
US20050118262A1 (en) Controlled release formulation
TW202327588A (zh) 治療神經膠質母細胞瘤之方法
WO2012039691A2 (en) Synergic effect
CN117412962A (zh) 用酞嗪酮衍生物治疗病症的方法
CN116322653A (zh) 包括酞嗪酮衍生物的药物组合物
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
CN108853033A (zh) 一种喹硫平药物制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230327

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250227

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250227

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250321

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250430

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250530